Pak J Med Sci:阿奇霉素和红霉素治疗小儿支原体肺炎的比较

2020-02-19 不详 网络

本研究旨在探究和对比阿奇霉素和红霉素对小儿支原体肺炎的临床疗效。纳入2017年11月至2018年9月期间入院的132例支原体肺炎患儿作为研究对象。根据随机数字表将所有儿童分为观察组和对照组,每组66个。观察组给予阿奇霉素治疗,对照组给予红霉素治疗。比较两组的治疗效果,不良反应发生率和临床症状消失时间。结果显示,观察组总有效率98.04%,对照组总有效率74.51%,有显著差异(X2 = 7.184

本研究旨在探究和对比阿奇霉素和红霉素对小儿支原体肺炎的临床疗效。

纳入2017年11月至2018年9月期间入院的132例支原体肺炎患儿作为研究对象。根据随机数字表将所有儿童分为观察组和对照组,每组66个。观察组给予阿奇霉素治疗,对照组给予红霉素治疗。比较两组的治疗效果,不良反应发生率和临床症状消失时间。

结果显示,观察组总有效率98.04%,对照组总有效率74.51%,有显著差异(X2 = 7.184,P = 0.007)。观察组不良反应发生率为15.69%,明显低于对照组(41.18%)(X2 = 6.376,P = 0.002)。观察组发热,咳嗽,罗音,X线影消失消失明显早于对照组,差异有统计学意义(P <0.05)。

综上所述,该研究结果表明,与红霉素相比,阿奇霉素在儿童支原体肺炎的治疗中更有效。阿奇霉素可进一步缩短临床症状和体征的改善时间,不良反应少,安全性高,值得临床应用。

原始出处:

Han R, Yu Q, et al., Comparison of azithromycin and erythromycin in the treatment of mycoplasma pneumonia in children. Pak J Med Sci. 2020 Jan-Feb;36(2):156-159. doi: 10.12669/pjms.36.2.1441.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1749222, encodeId=1a741e492222e, content=<a href='/topic/show?id=bc0fe7197d0' target=_blank style='color:#2F92EE;'>#红霉素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77197, encryptionId=bc0fe7197d0, topicName=红霉素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e02f36248491, createdName=wolongzxh, createdTime=Mon Jan 04 04:58:00 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610269, encodeId=e0e216102697c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Feb 21 07:58:00 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614722, encodeId=d2b71614e22bc, content=<a href='/topic/show?id=1f0a5e0662f' target=_blank style='color:#2F92EE;'>#支原体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57066, encryptionId=1f0a5e0662f, topicName=支原体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fb019527746, createdName=ms5906905816781247, createdTime=Fri Feb 21 07:58:00 CST 2020, time=2020-02-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1749222, encodeId=1a741e492222e, content=<a href='/topic/show?id=bc0fe7197d0' target=_blank style='color:#2F92EE;'>#红霉素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77197, encryptionId=bc0fe7197d0, topicName=红霉素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e02f36248491, createdName=wolongzxh, createdTime=Mon Jan 04 04:58:00 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610269, encodeId=e0e216102697c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Feb 21 07:58:00 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614722, encodeId=d2b71614e22bc, content=<a href='/topic/show?id=1f0a5e0662f' target=_blank style='color:#2F92EE;'>#支原体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57066, encryptionId=1f0a5e0662f, topicName=支原体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fb019527746, createdName=ms5906905816781247, createdTime=Fri Feb 21 07:58:00 CST 2020, time=2020-02-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1749222, encodeId=1a741e492222e, content=<a href='/topic/show?id=bc0fe7197d0' target=_blank style='color:#2F92EE;'>#红霉素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77197, encryptionId=bc0fe7197d0, topicName=红霉素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e02f36248491, createdName=wolongzxh, createdTime=Mon Jan 04 04:58:00 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610269, encodeId=e0e216102697c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Feb 21 07:58:00 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614722, encodeId=d2b71614e22bc, content=<a href='/topic/show?id=1f0a5e0662f' target=_blank style='color:#2F92EE;'>#支原体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57066, encryptionId=1f0a5e0662f, topicName=支原体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fb019527746, createdName=ms5906905816781247, createdTime=Fri Feb 21 07:58:00 CST 2020, time=2020-02-21, status=1, ipAttribution=)]